Opus Point Partners Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 2000 ETF
IWM
|
+$22.6M |
| 2 |
iShares Biotechnology ETF
IBB
|
+$4.76M |
| 3 |
State Street SPDR S&P Biotech ETF
XBI
|
+$3.22M |
| 4 |
GSK
GSK
|
+$2.11M |
| 5 |
IQVIA
IQV
|
+$1.44M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
+$3.11M |
| 2 |
ProShares Ultra NASDAQ Biotechnology
BIB
|
+$2.63M |
| 3 |
EPZM
Epizyme, Inc
EPZM
|
+$2.3M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$2.14M |
| 5 |
Pacira BioSciences
PCRX
|
+$1.86M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 63.14% |
| 2 | Miscellaneous | 35.99% |
| 3 | Real Estate | 0.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
51
Pacira BioSciences
PCRX
$949M
| – | – |
-35,110
| Closed | -$1.86M |
|
52
Vericel Corp
VCEL
$2.02B
| – | – |
-298,941
| Closed | -$1.75M |
|
|
CLVS
53
DELISTED
Clovis Oncology, Inc.
CLVS
| – | – |
-75,000
| Closed | -$1.44M |
|
|
EPZM
54
DELISTED
Epizyme, Inc
EPZM
| – | – |
-189,564
| Closed | -$2.3M |
|
|
DRNA
55
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| – | – |
-108,000
| Closed | -$579K |
|
|
ACHN
56
DELISTED
Achillion Pharmaceuticals
ACHN
| – | – |
-99,000
| Closed | -$764K |
|
|
ONCE
57
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| – | – |
-31,500
| Closed | -$930K |
|
|
LOXO
58
DELISTED
Loxo Oncology, Inc
LOXO
| – | – |
-36,000
| Closed | -$984K |
|
|
RXDX
59
DELISTED
Ignyta, Inc.
RXDX
| – | – |
-81,000
| Closed | -$548K |
|
|
MACK
60
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| – | – |
-11,439
| Closed | -$753K |
|
|
ZGNX
61
DELISTED
Zogenix, Inc.
ZGNX
| – | – |
-68,130
| Closed | -$630K |
|
Similar funds
Opus Point Partners Management's Q2 2016 Portfolio in Review
As of Q2 2016, Opus Point Partners Management held 61 positions worth $104M, down 20% from $129M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Opus Point Partners Management withdrew a net $7.19M in Q2 2016, closing 18 positions and reducing 31 holdings. Its most notable exit was ProShares Ultra NASDAQ Biotechnology, an estimated $2.63M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 73% a quarter earlier, followed by Miscellaneous and Real Estate.
Against the trend, Opus Point Partners Management opened a new position in iShares Russell 2000 ETF worth $23M.
- Opus Point Partners Management's largest Q2 2016 buy was iShares Russell 2000 ETF: 200,000 shares worth $23M.
- Opus Point Partners Management added most to AstraZeneca in Q2 2016, an estimated $856K increase.
- Opus Point Partners Management's biggest Q2 2016 reduction was MEDIVATION, INC., cutting an estimated $3.11M.
- Opus Point Partners Management fully exited ProShares Ultra NASDAQ Biotechnology in Q2 2016, selling an estimated $2.63M.
- Opus Point Partners Management's ten largest holdings make up 56% of its $104M portfolio in Q2 2016.
- Opus Point Partners Management opened 9 new positions and closed 18 in Q2 2016.
- Opus Point Partners Management's portfolio value fell 20% quarter-over-quarter to $104M.
Based on Opus Point Partners Management's 13F filing for Q2 2016, filed 15 Aug 2016.